Research Topics
| David M LoebSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Remission of severe autoimmune enteropathy after treatment with high-dose cyclophosphamideMaria M Oliva-Hemker
Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21187-2631, USA
J Pediatr Gastroenterol Nutr 36:639-43. 2003
Pediatric soft tissue sarcomasDavid M Loeb
Oncology and Pediatrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
Surg Clin North Am 88:615-27, vii. 2008..RMS is treated with adjuvant chemotherapy, whereas chemotherapy is reserved for the NRSTS that are high grade or unresectable. This review discusses the etiology, biology, and treatment of pediatric soft tissue sarcomas...- WT1 influences apoptosis through transcriptional regulation of Bcl-2 family membersDavid M Loeb
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Bunting Blaustein Cancer Research Building, Room 254, 1650 Orleans St, Baltimore, Maryland 21231 USA
Cell Cycle 5:1249-53. 2006..Thus, a complete understanding of the role of WT1 in apoptosis will have to account for lineage- and isoform-specific effects of WT1 at both the cellular and molecular levels... 
Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcomaDavid M Loeb
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Cancer 115:2514-22. 2009..The purpose of the current study was to determine the maximally tolerated dose of (153)Sm-EDTMP that permits hematopoietic recovery within 6 weeks...- Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcomaDavid M Loeb
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Cancer 116:5470-8. 2010..The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities... - Is there a role for immunotherapy in osteosarcoma?David M Loeb
Oncology and Pediatrics, Musculoskeletal Tumor Program, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Room 2M51, 1650 Orleans St, Baltimore, MD 21231, USA
Cancer Treat Res 152:447-57. 2009..This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma... - A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapyRobert F Hobbs
Johns Hopkins University, Baltimore, MD 21231, USA
Int J Radiat Oncol Biol Phys 80:1256-62. 2011..We have developed and tested a treatment planning method, using the patient-specific three-dimensional dosimetry package 3D-RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk... - Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcomaSrinivasan Senthamizhchelvan
Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
J Nucl Med 53:215-24. 2012..We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response... - The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesisSuzie Ariyaratana
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Expert Rev Mol Med 9:1-17. 2007..Alternative methods employing WT1-specific immunotherapy are being investigated and might ultimately be used to optimise multimodal therapy of haematological malignancies... - A clinical algorithm identifies high risk pediatric oncology and bone marrow transplant patients likely to benefit from treatment of adenoviral infectionKirsten Marie Williams
Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
J Pediatr Hematol Oncol 31:825-31. 2009.... - WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxiaGregory McCarty
Division of Pediatric Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland 21231, USA
J Biol Chem 286:43634-43. 2011..Taken together, these data demonstrate that VEGF is a direct, bona fide WT1 target gene in sarcoma and that WT1 plays a key role in optimizing the response of tumor cells to hypoxia... - The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapyLesley A Simpson
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
Blood 107:4695-702. 2006.... - A gamma camera count rate saturation correction method for whole-body planar imagingRobert F Hobbs
Johns Hopkins University, Baltimore MD, USA
Phys Med Biol 55:817-31. 2010..e. time-dependent dead-time effects. The algorithm presented here accomplishes this task... - Significant responses to platinum-based chemotherapy in renal medullary carcinomaJohn J Strouse
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
Pediatr Blood Cancer 44:407-11. 2005..We describe two adolescents with metastatic disease who had significant responses to cisplatin or carboplatin in combination with gemcitabine and paclitaxel... - WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology GroupSuzie A Noronha
Division of Pediatric Oncology, Department of Oncology, The Johns Hopkins Hospital, Baltimore, Maryland 21231, USA
Pediatr Blood Cancer 53:1136-9. 2009..Neither overall survival nor event-free survival was correlated with WT1 expression... - High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseasesAmy E Dezern
Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
Medicine (Baltimore) 90:89-98. 2011..7% and 20.6%, respectively. High-dose cyclophosphamide without stem cell rescue is well tolerated and induces a high rate of remission in severe autoimmune diseases... - Cyclin E is a target of WT1 transcriptional repressionDavid M Loeb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231, USA
J Biol Chem 277:19627-32. 2002..In intact cells, induction of WT1 expression down-regulates cyclin E protein levels. These results provide the first demonstration that WT1 can directly modulate the expression of a gene involved in cell cycle progression... - Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patientsSu Young Kim
Division of Pediatric Oncology, Department of Oncology, The Johns Hopkins Hospital, Baltimore, Maryland, USA
Pediatr Blood Cancer 50:779-83. 2008..We performed a retrospective analysis to determine the PCP breakthrough rate in pediatric oncology patients receiving intravenous pentamidine as second line PCP prophylaxis... - Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamideWilliam J Savage
Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA
Pediatr Blood Cancer 49:947-51. 2007..Demonstrate that high-dose cyclophosphamide (CY) is effective therapy for hepatitis-associated aplastic anemia (HAA)... - The role of WT1 in oncogenesis: tumor suppressor or oncogene?David M Loeb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Int J Hematol 76:117-26. 2002..The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed... - Cardiac metastasis and hypertrophic osteoarthropathy in recurrent infantile fibrosarcomaNirali N Shah
Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, Baltimore, Maryland 21287, USA
Pediatr Blood Cancer 59:179-81. 2012..Autopsy demonstrated a metastatic lesion in the intraventricular septum of the heart, which is previously undescribed in the literature. This case demonstrates that IF can be aggressive despite its more typical benign course... - Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular targetWesley Hsu
Department of Neurosurgery and Oncology, Brain Tumor Stem Cell Laboratory, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
J Neurosurg 115:760-9. 2011..Thus, the objective of this study was to establish the first fully characterized primary chordoma cell line expressing gain of the T gene locus that readily recapitulates the original parental tumor phenotype in vitro and in vivo... - What is the optimal therapy for childhood AML?David M Loeb
Johns Hopkins Oncology Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
Oncology (Williston Park) 16:1057-66; discussion 1066, 1068-70. 2002.... - Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapyDavid M Loeb
Department of Oncology Johns Hopkins University, Baltimore, Maryland, USA
J Pediatr Hematol Oncol 24:478-81. 2002..Based on these patients and a review of the literature, the authors suggest that chemotherapy be considered as a part of the therapy for recurrent or unresectable cellular CMN... - Congenital T cell deficiency in a patient with CHARGE syndromeJulie Hoover-Fong
McKusick Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA
J Pediatr 154:140-2. 2009..We report a patient with molecularly confirmed CHARGE syndrome, which included a congenital T cell deficiency, who was treated with peripheral blood mononuclear cell transplantation... - Treatment and outcome of infants with acute myeloid leukemiaDavid M Loeb
Blood 99:2626-7. 2002